Doximity upgraded to Buy from Neutral at BTIG

BTIG analyst David Larsen upgraded Doximity (DOCS) to Buy from Neutral with an $80 price target Although there is macro uncertainty with respect to the biopharma industry, including the risk of tariffs, ongoing drug pricing reform, the Inflation Reduction Act, and Medicare rate pressures, demand for high-quality, precise, software-as-a-service commercialization efforts will continue to rise, the analyst tells investors in a research note. The firm believes Doximity’s recent fiscal 2026 guidance is likely conservative and accounts for macro risks. The company has $900M of cash, no debt, and high gross and EBITDA margins relative to the group, contends BTIG.